A Prognostic Index for Patients with Refractory or in First Relapsed Acute Myeloid Leukemia Treated with FLAG-Ida or Flago-Ida

INTRODUCTION AND AIMS Almost seventy percent of Acute Myeloid Leukemia (AML) patients will relapse. Fludarabine, Ara-C, Idarrubicine, G-CSF (FLAG-Ida) and FLAG-Ida and Gentuzumab-Ozogamicin (FLAGO-Ida) is frequently used before allogenic stem cell transplant (ASCT). There are several studies analyzi...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2014-12, Vol.124 (21), p.1049-1049
Main Authors: Bergua, Juan Miguel, Montesinos, Pau, Martinez-Cuadrón, David, Fernández-Abellán, Pascual, Serrano, Josefina, Sayas, María José, Prieto-Fernandez, Julio, Garcia, Raimundo, Garcia-Huerta, Ana Julia, Barrios, Manuel, Pérez-López, Cristina, Perez-Encinas, Manuel, Siemele, Adriana, Rodriguez-Macias, Gabriela, Herrera-Puente, Pilar, Rodríguez-Veiga, Rebeca, Martinez-Sanchez, Maria Pilar, Amador-Barciela, Maria Lourdes, Sanz, Miguel A.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTION AND AIMS Almost seventy percent of Acute Myeloid Leukemia (AML) patients will relapse. Fludarabine, Ara-C, Idarrubicine, G-CSF (FLAG-Ida) and FLAG-Ida and Gentuzumab-Ozogamicin (FLAGO-Ida) is frequently used before allogenic stem cell transplant (ASCT). There are several studies analyzing the risk factors for survival in relapsed/refractory patients, but none of them were performed exclusively in patients treated with FLAG-Ida. We analyzed the results of in the Spanish trials conducted by PETHEMA. We also present a predictive score system of survival prognosis based on the data of the patients enrolled METHODS This is a retrospective, multicentre study of the PETHEMA AML epidemiologic Registry. In PETHEMA protocols 98,99,2007,2010 and 2011, FLAG-Ida was included as salvage treatment in patients relapsed or resistant after a 2ndinduction based in 3+7. In PETHEMA trial 2007, FLAG-Ida (or FLAGO-Ida) was administered if complete remission (CR) was not attained in the first induction cycle. The use of FLGO in PETHEMA 2007 trial depended on the availability of GO for each centre. We use overall survival (OS) as final end point of the analysis. Univariate survival analysis was performed by Long-Rank test. Stepwise backward variable selection and Cox proportional hazard multivariable analysis was performed (covariables selected if p
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V124.21.1049.1049